Bioatla Inc (BCAB) - Net Assets
Based on the latest financial reports, Bioatla Inc (BCAB) has net assets worth $-37.31 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.57 Million) and total liabilities ($45.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Bioatla Inc (BCAB) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-37.31 Million |
| % of Total Assets | -435.55% |
| Annual Growth Rate | N/A |
| 5-Year Change | -117.17% |
| 10-Year Change | N/A |
| Growth Volatility | 129.37 |
Bioatla Inc - Net Assets Trend (2018–2025)
This chart illustrates how Bioatla Inc's net assets have evolved over time, based on quarterly financial data. Explore Bioatla Inc (BCAB) cash flow conversion to assess how effectively this company generates cash.
Annual Net Assets for Bioatla Inc (2018–2025)
The table below shows the annual net assets of Bioatla Inc from 2018 to 2025. For live valuation and market cap data, see BCAB market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-36.19 Million | -353.69% |
| 2024-12-31 | $14.27 Million | -79.82% |
| 2023-12-31 | $70.67 Million | -60.81% |
| 2022-12-31 | $180.34 Million | -14.46% |
| 2021-12-31 | $210.82 Million | +0.40% |
| 2020-12-31 | $209.97 Million | +474.88% |
| 2019-12-31 | $-56.01 Million | -96.90% |
| 2018-12-31 | $-28.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bioatla Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42708600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | % |
| Other Components | $509.45 Million | % |
| Total Equity | $-36.19 Million | 100.00% |
Bioatla Inc Competitors by Market Cap
The table below lists competitors of Bioatla Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Silver Bull Resources Inc
TO:SVB
|
$5.53 Million |
|
Rectifier Technologies Ltd
AU:RFT
|
$5.53 Million |
|
Euro Trend Yatirim Ortakligi AS
IS:ETYAT
|
$5.54 Million |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
$5.54 Million |
|
GEOTRANS S.A. ZY -10
F:5Z4
|
$5.53 Million |
|
Modern Times Group Mtg AB
ST:MTG-A
|
$5.52 Million |
|
Aptorum Group Ltd Class A
NASDAQ:APM
|
$5.52 Million |
|
Beauce Gold Fields Inc
V:BGF
|
$5.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioatla Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,265,000 to -36,189,000, a change of -50,454,000 (-353.7%).
- Net loss of 59,607,000 reduced equity.
- Share repurchases of 100,000 reduced equity.
- Other factors increased equity by 9,253,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-59.61 Million | -164.71% |
| Share Repurchases | $100.00K | -0.28% |
| Other Changes | $9.25 Million | +25.57% |
| Total Change | $- | -353.69% |
Book Value vs Market Value Analysis
This analysis compares Bioatla Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-65.93 | $3.55 | x |
| 2019-12-31 | $-83.12 | $3.55 | x |
| 2020-12-31 | $311.87 | $3.55 | x |
| 2021-12-31 | $305.00 | $3.55 | x |
| 2022-12-31 | $231.64 | $3.55 | x |
| 2023-12-31 | $73.96 | $3.55 | x |
| 2024-12-31 | $14.68 | $3.55 | x |
| 2025-12-31 | $-30.76 | $3.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioatla Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2980.35%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-98.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -272.69% | 0.64x | 0.00x | $-26.13 Million |
| 2019 | 0.00% | -572.96% | 0.56x | 0.00x | $-24.20 Million |
| 2020 | -17.07% | -8357.34% | 0.00x | 1.17x | $-56.85 Million |
| 2021 | -45.25% | -38160.80% | 0.00x | 1.21x | $-116.48 Million |
| 2022 | -58.38% | 0.00% | 0.00x | 1.25x | $-123.32 Million |
| 2023 | -174.70% | 0.00% | 0.00x | 1.69x | $-130.53 Million |
| 2024 | -489.14% | -634.33% | 0.21x | 3.67x | $-71.20 Million |
| 2025 | 0.00% | -2980.35% | 0.14x | 0.00x | $-55.99 Million |
Industry Comparison
This section compares Bioatla Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioatla Inc (BCAB) | $-37.31 Million | 0.00% | N/A | $5.53 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); a… Read more